Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Achieve Life Sciences Inc(ACHV)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ACHV
10/07/2026: ACHV (1-star) is currently NOT-A-BUY. Pass it for now.
Achieve Life Sciences is a clinical-stage biotechnology company developing cytisinicline, a potential treatment for smoking and nicotine addiction. Its primary strength lies in the successful progression of its late-stage clinical trials, which offer a unique mechanism for aiding cessation. The core investment story centers on the potential FDA approval of its flagship drug, which could address a massive market for smoking cessation. However, the company faces significant execution and financial risks, as it relies on a single asset and lacks a commercial footprint. This stock is best suited for speculative growth investors who can monitor clinical milestones and regulatory developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The growth potential is high if the product succeeds, but it is speculative and binary. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may trade on volatility surrounding clinical trial milestones and news cycles. |
| Value investor | Weak fit | The lack of earnings and assets makes it unsuitable for traditional value investing. |
| Dividend investor | Weak fit | The company does not pay dividends and is focused on capital preservation for R&D. |
| Low-risk investor | Weak fit | The speculative nature of drug development carries high risk of total loss of investment. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp swings based on clinical news and sector sentiment. |
| Valuation risk | High | Valuations are based on future potential rather than current financial performance. |
| Competition risk (nicotine cessation products) | Medium / high | Established products and low-cost generics create high barriers to entry. |
| Business quality | Medium | The business relies on a single clinical-stage asset, limiting portfolio diversification. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | High | Success depends on complex regulatory hurdles and clinical trial outcomes. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -42.9% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/07/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 724.81M USD | Price to earnings Ratio - | 1Y Target Price 14.15 |
Price to earnings Ratio - | 1Y Target Price 14.15 | ||
Volume (30-day avg) 1.6M shares | Beta 2.31 | 52 Weeks Range 2.62 - 8.64 | Updated Date 10/07/2026 |
52 Weeks Range 2.62 - 8.64 | Updated Date 10/07/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.69 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research, clinical trials, and regulatory filing activities for cytisinicline. | The company currently has no commercial revenue and is investing all capital into getting its lead drug approved. |
Valuation
Trailing PE - | Forward PE 35.34 | Enterprise Value 663.21M | Price to Sales(TTM) 5.09 |
Enterprise Value 663.21M | Price to Sales(TTM) 5.09 | ||
Enterprise Value to Revenue 0.63 | Enterprise Value to EBITDA -2.42 | Shares Outstanding 103.10M | Shares Floating 74.69M |
Shares Outstanding 103.10M | Shares Floating 74.69M | ||
Percent Insiders 0.91 | Percent Institutions 82.09 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Achieve Life Sciences Inc
Exchange NASDAQ | Headquarters Bothell, WA, United States | ||
IPO Launch date 1995-10-13 | CEO, President & Director Dr. Andrew D. Goldberg M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | |
Full time employees 28 | |||
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.